8-K: Masimo Q2 2025 Earnings: Strong Growth, Tariff Mitigation

Masimo Corporation reported strong second quarter 2025 financial results, driven by core healthcare business growth and effective tariff mitigation, while updating its full-year guidance.

Summary

• GAAP revenue for the second quarter ended June 28, 2025, was $370.9 million, representing 8% growth on a reported basis.
• Non-GAAP revenue for Q2 2025 was $370 million, representing 7% growth on a constant currency basis.
• GAAP net income per diluted share for Q2 2025 was $0.82.
• Non-GAAP net income per diluted share for Q2 2025 was $1.33, which grew 46% versus the prior year period.
• Non-GAAP operating profit for Q2 2025 was $102 million, growing 38% versus prior year, with an operating margin of 27.5%, an improvement of 600 basis points.
• Updated full-year 2025 Non-GAAP revenue guidance is $1,505 to $1,535 million, increasing 8% to 11% on a constant currency basis.
• Updated full-year 2025 Non-GAAP operating profit guidance, including the impact of new tariffs, is $406 to $422 million.
• Updated full-year 2025 Non-GAAP earnings per diluted share guidance, including the impact of new tariffs, is $5.20 to $5.45.
• The estimated financial impact of new tariffs for fiscal 2025 is a $17 to $19 million increase to cost of sales, representing a 120 to 130 basis point impact to operating margin and a $0.25 impact to EPS, net of mitigation implemented to date.
• Tariff mitigation measures have reduced the estimated tariff impact by 50% compared to the original estimate.
• The incremental value of new contracts in Q2 2025 was $80 million.
• Unrecognized contract revenue was $1,720 million.
• Masimo shipped 63,100 technology boards and instruments in Q2 2025.
• Consumable and Service revenue was $338 million, growing 8% on a constant currency basis.
• Capital and Other revenue was $32 million, decreasing 2% on a constant currency basis.

Sentiment

Score: 8

Explanation: Masimo's Q2 2025 results demonstrate robust growth in its core healthcare business, with significant increases in non-GAAP earnings and operating profit. The company's proactive and successful mitigation of tariff impacts, reducing the estimated financial burden by 50%, is a strong positive indicator of effective management. The upward revision of full-year guidance, despite ongoing tariff challenges, signals confidence in future performance. The strong balance sheet with healthy cash flow from operations further supports a positive outlook.

Positives

• Achieved strong Q2 2025 results with GAAP revenue growth of 8% and Non-GAAP net income per diluted share growth of 46% versus the prior year period.
• Core healthcare business demonstrated strong growth and earnings.
• Successfully implemented tariff mitigation measures, reducing the estimated tariff impact by 50% from the original estimate.
• Expanded the leadership team to strengthen execution of the growth strategy.
• Improved Non-GAAP operating margin by 600 basis points to 27.5% in Q2 2025.
• Updated full-year 2025 guidance shows increased projections for revenue, operating profit, and EPS.
• Incremental value of new contracts was $80 million, indicating continued business expansion.
• Unrecognized contract revenue of $1,720 million provides a strong foundation for future revenue streams.
• Consumable and Service revenue, a key recurring revenue stream, grew 8% on a constant currency basis.

Negatives

• New tariffs are expected to increase cost of sales by $17 to $19 million for fiscal 2025, impacting operating margin by 120 to 130 basis points and EPS by $0.25.
• Capital and Other revenue decreased 2% on a constant currency basis in Q2 2025.
• Reported a net loss of $(119.4) million for the six months ended June 28, 2025, primarily due to loss from discontinued operations.

Risks

• Dependence on Masimo SET and Masimo rainbow SET products and technologies for substantially all revenue.
• Potential failure in protecting intellectual property.
• Exposure to competitors' assertions of intellectual property claims.
• Highly competitive nature of the markets in which products and technologies are sold.
• Potential failure to continue developing innovative products and technologies.
• Ability to address and expand into new markets.
• Lack of acceptance of any current or future products and technologies.
• Challenges in obtaining regulatory approval of current and future products and technologies.
• Risk that the implementation of international realignment will not continue to produce anticipated operational and financial benefits, including a continued lower effective tax rate.
• Loss of customers.
• Failure to retain and recruit senior management.
• Matters relating to future board and management leadership.
• Exposure to product liability claims.
• Failure to obtain expected returns from recorded intangible assets.
• Challenges in maintaining the brand.
• Impact of the amount and type of equity awards granted to employees and service providers in the future.
• Ongoing litigation and related matters, including various proceedings against Apple.
• Ability to effect any potential separation of the non-healthcare consumer audio business (Sound United) and to meet any related conditions.
• Approval of any potential separation by Masimo's board of directors.
• Ability of any separated businesses to be successful.
• Potential uncertainty during the pendency of any potential separation that could affect Masimo's financial performance.
• Possibility that any potential separation will not be completed within the anticipated time period or at all.
• Possibility that any potential separation will not achieve its intended benefits.
• Possibility of disruption, including changes to existing business relationships, disputes, litigation or unanticipated costs in connection with any potential separation.
• Impact on employees from any potential separation.
• Uncertainty of the expected financial performance of Masimo prior to and following completion of any potential separation.
• Negative effects of the announcement or pendency of any potential separation on the market price of Masimo's securities and/or on its financial performance.
• Evolving legal, regulatory and tax regimes.
• Potential negative effects or impact on the business from new international trade tariffs and tax law changes.
• Changes in general economic and/or industry specific conditions.
• Actions by third parties, including government agencies.

Future Outlook

Masimo updated its full-year 2025 guidance for continuing operations, projecting Non-GAAP revenue of $1,505 to $1,535 million, an increase of 8% to 11% on a constant currency basis. Non-GAAP operating profit is expected to be $406 to $422 million, and Non-GAAP earnings per diluted share are projected to be $5.20 to $5.45, both including the impact of new tariffs. The company anticipates the impact of tariffs to increase each quarter over the remainder of the year as costs are capitalized into inventory and then recognized.

Management Comments

• "We once again delivered strong results in the second quarter as our core health care business continued to demonstrate strong growth and earnings."
• "We are intensely focused on building our leading position in pulse oximetry to increase our market share in key global markets and advanced monitoring categories, and on driving commercial excellence throughout the organization."
• "We have also expanded our leadership team to ensure that we have the right people and pillars in place to execute our growth strategy."
• "Notably, our team has been highly effective in the implementation of tariff mitigation measures, allowing us to guide to a tariff impact that is 50% less than our original estimate."
• "Each of these factors is contributing to our positive momentum and we are investing in our core healthcare business to achieve our goals and potentially accelerate our long-range revenue growth."

Industry Context

Masimo operates in the medical technology sector, specializing in non-invasive patient monitoring, particularly pulse oximetry. The company's focus on expanding its market share in key global markets and advanced monitoring categories aligns with broader industry trends towards enhanced patient safety, efficiency, and connectivity in healthcare. The emphasis on core healthcare business growth suggests a strategic focus on its established strengths amidst a dynamic market, while actively managing external challenges like tariffs.

Comparison to Industry Standards

• NA

Legal Proceedings

• Engaged in various legal proceedings against Apple since January 2020, including federal court proceedings, U.S. Patent and Trademark Office (PTO proceedings), and a U.S. International Trade Commission (ITC proceeding).
• Litigation related expenses and settlements, specifically all Apple litigation expenses, are excluded from non-GAAP adjustments due to their unique nature and non-indicative status of ongoing operating performance.

Related Party Transactions

• Reported related party revenue of $25.8 million for the three months ended June 28, 2025, and $57.6 million for the six months ended June 28, 2025.
• Reported related party receivables of $17.4 million as of June 28, 2025.

Stakeholder Impact

• Shareholders: Positive impact from strong financial results, increased guidance, and effective tariff mitigation, potentially leading to increased share value.
• Employees: Positive impact from expanded leadership team and continued investment in the core healthcare business, suggesting stability and growth opportunities.
• Customers: Continued focus on building a leading position in pulse oximetry and advanced monitoring categories, aiming to improve patient outcomes and reduce care costs.
• Suppliers: Potential adjustments to supply chain processes and manufacturing locations due to tariff mitigation efforts, which could impact existing supplier relationships.
• Creditors: Improved financial health and operating profit may enhance creditworthiness.

Next Steps

• Conduct a conference call on August 5, 2025, at 4:30 p.m. Eastern Time to review supplemental information and updated outlook for the remainder of fiscal 2025.
• Continue investing in the core healthcare business to achieve goals and potentially accelerate long-range revenue growth.
• Implement additional medium-term tariff mitigation measures, including adjusting supply chain processes, adjusting manufacturing processes, and moving patient cables out of China.

Key Dates

Recommendation

Masimo's Q2 2025 results demonstrate robust growth in its core healthcare business, with significant increases in non-GAAP earnings and operating profit. The company's proactive and successful mitigation of tariff impacts, reducing the estimated financial burden by 50%, is a strong positive indicator of effective management. The upward revision of full-year guidance, despite ongoing tariff challenges, signals confidence in future performance. The strong balance sheet with healthy cash flow from operations further supports a positive outlook. The strategic focus on expanding market share in key healthcare segments and continued innovation in patient monitoring technologies positions the company for sustained long-term growth, making it an attractive investment.

Keywords

Medical Technology, Healthcare, Patient Monitoring, Pulse Oximetry, Financial Results, Earnings, Tariffs, Corporate Guidance, Risk Management, Strategic Business Analysis, SEC Filing, MASI